Understanding the Ozempic Gastroparesis Lawsuit: A Comprehensive Overview
Estimated Reading Time: 8 minutes
- Thousands of lawsuits allege Ozempic and similar drugs cause gastroparesis.
- Manufacturers face accusations of inadequate warnings and negligent testing.
- Potential financial implications for pharmaceutical companies are significant.
- Eligibility criteria for lawsuits include specific diagnoses and medication use.
- Victims experience debilitating symptoms, impacting their lives severely.
The Ozempic Gastroparesis Lawsuit: What You Need to Know
Lawsuits against Novo Nordisk and Eli Lilly and Co. allege that their GLP-1 receptor agonist drugs—including Ozempic, Wegovy, Rybelsus, Mounjaro, and Trulicity—cause severe gastrointestinal side effects, primarily gastroparesis (stomach paralysis). Plaintiffs contend that the manufacturers failed to adequately warn patients and healthcare providers of this significant risk, leading to debilitating health consequences and substantial financial losses.
The core argument hinges on the drugs’ mechanism of action. While the delayed gastric emptying contributes to weight loss and improved blood sugar control, it can also severely disrupt the normal functioning of the stomach. For some individuals, this disruption manifests as gastroparesis, characterized by symptoms ranging from persistent nausea and vomiting to severe stomach pain and even intestinal blockage.
The sheer scale of the litigation is striking. Initially launched with a single lawsuit in August 2023, the Ozempic gastroparesis lawsuit, along with similar claims against other GLP-1 RAs, has consolidated into MDL No. 3094 in the Eastern District of Pennsylvania. As of September 2025, over 2,190 lawsuits are pending, a number projected to grow considerably. The potential financial implications for the pharmaceutical companies are immense, with some experts predicting settlements or judgments exceeding $2 billion.
Key Allegations Against the Manufacturers
- Inadequate Warnings: Plaintiffs argue that the manufacturers failed to adequately warn about the potential for severe gastrointestinal side effects, including gastroparesis, ileus (bowel obstruction), and intestinal blockage. The warning labels, they claim, understated the risk and its severity.
- Negligent Testing and Monitoring: Lawsuits contend that the companies were negligent in their post-approval testing and monitoring of the drugs, failing to identify and appropriately address the potential for gastroparesis at an earlier stage.
- Suppression of Information: Some plaintiffs suggest that the companies may have actively suppressed or downplayed information regarding the risk of gastroparesis to protect their market share and profits. This claim, however, requires significant evidence to support.
Who is Affected? Eligibility for the Ozempic Gastroparesis Lawsuit
Determining eligibility for participation in the Ozempic gastroparesis lawsuit requires meeting specific criteria. Generally, individuals must have:
- Taken Ozempic, Wegovy, Rybelsus, Mounjaro, or Trulicity.
- Subsequently developed severe gastroparesis, often defined as persistent vomiting for four weeks or more.
- A properly performed gastric emptying study confirming delayed gastric emptying at the time of diagnosis (as per Judge Marston’s August 2025 ruling).
Crucially, individuals who underwent gastric bypass, gastric banding, or gastric sleeve surgery before taking the medication, or those currently undergoing cancer treatment, are generally excluded from these lawsuits.
Reported Injuries and Symptoms
- Gastroparesis: The primary injury, characterized by impaired stomach muscle function, leading to delayed or incomplete emptying of the stomach.
- Nausea and Vomiting: Severe and persistent nausea and vomiting, often leading to dehydration and malnutrition.
- Stomach Pain: Intense and persistent stomach pain and gastrointestinal burning.
- Intestinal Blockage/Ileus: Severe complications that can require hospitalization and surgery.
- Difficulty Swallowing: Dysphagia, making eating and drinking extremely difficult.
- Rectal Bleeding: In some cases, significant rectal bleeding has been reported.
- Malnutrition: Significant weight loss due to the inability to adequately absorb nutrients.
- Other Serious Side Effects: Beyond gastrointestinal issues, lawsuits also cite vision loss (NAION), pancreatitis, pulmonary embolisms, DVT, gallbladder disorders, and kidney damage.
The Legal Process and Potential Outcomes
The consolidated MDL allows for efficient handling of the numerous lawsuits. The process involves discovery, where evidence is gathered from both sides, followed by potential settlement negotiations or trials. While no settlements have been reached as of September 2025, the sheer number of cases and the severity of the alleged injuries suggest significant financial implications. Plaintiffs are seeking compensation for medical expenses, lost wages, pain and suffering, and potentially punitive damages.
Practical Takeaways and Actionable Advice
If you or someone you know has experienced severe gastrointestinal issues after taking Ozempic or a similar medication, it’s crucial to:
- Consult with a medical professional: Obtain a proper diagnosis and thorough medical records.
- Document all symptoms and medical expenses: Keep detailed records of your medical history, treatment, and financial burdens.
- Seek legal counsel: Consult with an experienced attorney specializing in pharmaceutical litigation to explore your legal options.
The Ozempic gastroparesis lawsuit is a rapidly evolving situation. Staying informed about developments and understanding your rights is essential.
Call to Action: Contact us today for a free consultation to discuss your potential claim. Our team of experienced pharmaceutical litigation lawyers is ready to assist you. Don’t delay – the statute of limitations may apply.